ASH 2022 | Phase II study of venetoclax and azacitidine vs induction chemotherapy in fit patients with AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses a phase II clinical trial (NCT04801797) comparing venetoclax and azacitidine to conventional induction chemotherapy in the treatment of newly diagnosed fit adults with acute myeloid leukemia (AML). This treatment is already used in high-risk and older patients as conventional chemotherapy treatment for AML causes significant complications. This trial is currently in progress and is expected to confirm that venetoclax and azacitidine leads to increased or similar event-free survival (EFS) rates and better tolerability compared to conventional induction chemotherapy in fit patients. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy – Genentech, BMS/Celgene, Foghorn, Kite, Morphosys, Abbvie, Takeda, Ipsen, Forma, Amgen, Novartis, Astellas, Immunogen, Mablytics, EnClear, Orum, PureTech, Daiichi Sankyo, Pfizer; Research funding – BMS/Celgene, Abbvie, Agios/Servier
